Overview

Tranexamic Acid Dosing in Adult Spinal Deformity Surgery

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate two dosing protocols for tranexamic acid (TXA), an anti-fibrinolytic used to decrease blood loss in adult patients undergoing complex, reconstructive spinal fusion surgeries.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
AOSpine North America
Treatments:
Tranexamic Acid